Food and Drug Administration, and other national and international public funders. My research has been funded by the National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Agency for Healthcare Research and Quality, the U.S. Yu-Li Cheng (2021.3-2021.5 2021.10-2022.2 2022.8-2022.9)Ĭhi-Wei Huang (2021.8-2021.9 primary goal of my research is to develop, evaluate, and disseminate efficient methods for comparing healthcare interventions and to provide trust-worthy evidence for decision-making. Pharmaceutics, pharmaceutical analysis, regulatory science Scholarship from Taiwan Fujisawa Medical Research Development Foundation (2001) Graduated from university with best grade (2001)ġ1.Ěward for excellence in pharmacy internship at National Taiwan University Hospital (2001)ġ2. Passing the pharmacy licensing exam with best grade (2001)ġ0. Graduated with award for excellence in academic performance (2003)ĩ. Student travel grant, Pharmaceutical Sciences World Congress (2004)Ĩ. Honorary member, The Phi Tau Phi Scholastic Honor Society at National Taiwan University (2001, 2003, 2005, 2006)ħ. Outstanding performer award, best team award, and leader of best team of 2007 Novartis International Biotechnology Leadership Camp (international event held in Tokyo) best performer of 2007 Novartis International Biotechnology Leadership Camp in Taipei (local selection event held in Taipei)Ħ. The published paper entitled “he clinical implications of blood adiponectin in cardiometabolic disorders” was awarded by the journal, Journal of the Formosan Medical Association, as the most valuable paper in 2011. National Taiwan University Outstanding Teaching Award (Academic Year 2019, 2020) (2020, 2021)ģ.ğirst prize, 2016 Center of Excellence in Regulatory Science and Innovation (CERSI) Writing Competition in Johns Hopkins University (2016)Ĥ. National Taiwan University, College of Medicine, School of Pharmacy, Outstanding Teaching Award in Basic Science (Academic Year 2021) (2022)Ģ. Postdoctoral researcher, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University (2007.1-2008.8)ġ. (4) Reviewer, Chemistry, Manufacturing and Controls Team, Division of Preclinical Sciences (2008.10-2011.9) (3) Visiting Expert in European Medicines Agency (2011.3) (2) Team leader, Chemistry, Manufacturing and Controls Team II, Division of Pharmaceutical Science (formerly named Division of Preclinical Sciences) (2011.10-2015.3) Technical expert, Department of Pharmacy, College of Medicine, National Taiwan University (2012.2-2017.7) Instructor, School of Pharmacy, College of Medicine, National Taiwan University (2017.8-2019.1) Master of Science in Regulatory Science, Zanvyl Krieger School of Arts and Sciences, Johns Hopkins University (2017)īachelor of Science in Pharmacy, Department of Pharmacy, College of Medicine, National Taiwan University (2001)Įditorial Committee Member, Editorial Board of the Chinese Pharmacopeia, 10th ed., Ministry of Health and Welfare, Taiwan (2022.1-2024.12)Įditor, Editorial Board, Journal of Food and Drug Analysis (2022.1-2023.12)Ĭo-principal investigator, Platform for Research and Inspiration in Regulatory Science, School of Pharmacy, College of Medicine, National Taiwan University (2021.1-)Īdjunct Assistant Researcher, Department of Pharmacy, National Taiwan University hospital (2019.8-2023.7)Ĭommittee Member, Review Committee for Rare Diseases and Orphan Drugs (Sub-committee for Orphan Drugs), Ministry of Health and Welfare, Taiwan (2020.1-2021.12)Ĭommittee Member, Drug Advisory Committee, Ministry of Health and Welfare, Taiwan (2018.1-2018.12) Master of Science, Department of Pharmaceutical Sciences, College of Medicine, National Taiwan University (2003)
Doctor of Philosophy, Department of Pharmaceutical Sciences, College of Medicine, National Taiwan University (2006)
0 kommentar(er)
